WO2010108251A3 - Complexe moléculaire antinéoplasique-testostérone - Google Patents

Complexe moléculaire antinéoplasique-testostérone Download PDF

Info

Publication number
WO2010108251A3
WO2010108251A3 PCT/BR2010/000161 BR2010000161W WO2010108251A3 WO 2010108251 A3 WO2010108251 A3 WO 2010108251A3 BR 2010000161 W BR2010000161 W BR 2010000161W WO 2010108251 A3 WO2010108251 A3 WO 2010108251A3
Authority
WO
WIPO (PCT)
Prior art keywords
testosterone
antineoplastic
drug
molecular
molecular complex
Prior art date
Application number
PCT/BR2010/000161
Other languages
English (en)
Portuguese (pt)
Other versions
WO2010108251A2 (fr
Inventor
Gerson Silva Paiva
Original Assignee
Universidade Federal De Pernambuco - Ufpe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Pernambuco - Ufpe filed Critical Universidade Federal De Pernambuco - Ufpe
Publication of WO2010108251A2 publication Critical patent/WO2010108251A2/fr
Publication of WO2010108251A3 publication Critical patent/WO2010108251A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un complexe moléculaire antinéoplasique-testostérone comprenant une chaîne moléculaire de testostérone (1), un médicament antinéoplasique et un pont moléculaire ou une molécule. Le présent composé se caractérise en ce qu'il renferme une molécule de testostérone (1) liée chimiquement à un médicament antinéoplasique commercialement disponible, tel que la daunorubicine ou la doxorubicine (2), la cisplatine (3), la carboplatine (4) ou la combinaison cisplatine-bérénil (5), au moyen d'un pont moléculaire de type carbamate (6) ou d'une molécule de N',N-disuccnimidyl carbonate (7). Le complexe moléculaire permet de "guider" le médicament anticancéreux directement sur la tumeur. Le médicament peut ainsi agir sélectivement sur la prostate, ce qui permet d'éviter les effets sur les tissus sains, ce type de cancer nécessitant une grande quantité de testostérone pour se développer.
PCT/BR2010/000161 2009-03-27 2010-03-26 Complexe moléculaire antinéoplasique-testostérone WO2010108251A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0901157-9 2009-03-27
BRPI0901157-9A BRPI0901157A2 (pt) 2009-03-27 2009-03-27 complexo molecular antineoplásico-testosterona

Publications (2)

Publication Number Publication Date
WO2010108251A2 WO2010108251A2 (fr) 2010-09-30
WO2010108251A3 true WO2010108251A3 (fr) 2010-12-02

Family

ID=42781589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2010/000161 WO2010108251A2 (fr) 2009-03-27 2010-03-26 Complexe moléculaire antinéoplasique-testostérone

Country Status (2)

Country Link
BR (1) BRPI0901157A2 (fr)
WO (1) WO2010108251A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123911A1 (fr) * 2010-04-09 2011-10-13 Universidade Federal De Pernambuco - Ufpe Composés antitumoraux à base de testostérone et d'agent chimiothérapeutique
BRPI1101556A2 (pt) * 2011-04-19 2015-07-14 Univ Fed De Pernambuco Ufpe Composto antitumoral testosterona - ( iodo radioativo)
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021097046A1 (fr) 2019-11-13 2021-05-20 Nuvation Bio Inc. Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
AU2022246058A1 (en) 2021-03-23 2023-10-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRMU8701986U2 (pt) * 2007-09-28 2010-02-23 Gerson Silva Paiva complexo molecular antineoplásico-testosterona

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRMU8701986U2 (pt) * 2007-09-28 2010-02-23 Gerson Silva Paiva complexo molecular antineoplásico-testosterona

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMINSHARIFI AR ET AL.: "A postulated role of testosterone for prevention of cisplatin gonadal toxicity.", MED HYPOTHESES., vol. 68, no. 3, 2007, pages 525 - 527 *
KIDANI Y ET AL.: "Antitumor activity of steroid- containing platinum (II) complexes of IR,2R-cyclohexanediamine and 2- (aminomethyl)-cyclohexylamine isomers against leukemia L1210.", BIOMED PHARMACOTHER., vol. 43, no. 4, 1989, pages 261 - 264 *
MAINES MD.: "Effect of cis-platinum on heme, drug, and steroid metabolism pathways: possible involvement in nephrotoxicity an infertility.", CRIT REV TOXICOL., vol. 21, no. 1, 1990, pages 1 - 20 *
MURUGKAR A ET AL.: "Hormone anchored metal complexes. 1. Synthesis, structure, spectroscopy and in vitro antitumor activity of testosterone acetate thiosemicarbazone and its metal complexes.", METAL BASED DRUGS., vol. 6, no. 3, 1999, pages 177 - 182 *
SCHERTL S ET AL.: "Platinum (II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers?", PRECLINICAL STUDIES. J CANCER RES CLIN ONCOL., vol. 133, no. 3, 2007, pages 153 - 167 *
SEETHALAKSHMI L ET AL.: "Effects of subchronic treatment with cis-platinum on testicular function, fertility, pregnancy outcome, and progeny.", J. ANDROL., vol. 13, no. 1, 1992, pages 65 - 74 *
SEIFTER EJ ET AL.: "A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.", J CLIN ONCOL., vol. 4, no. 9, 1986, pages 1365 - 1373 *

Also Published As

Publication number Publication date
BRPI0901157A2 (pt) 2010-11-16
WO2010108251A2 (fr) 2010-09-30

Similar Documents

Publication Publication Date Title
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
WO2010108251A3 (fr) Complexe moléculaire antinéoplasique-testostérone
WO2009120697A3 (fr) Méthode et compositions pour le traitement du cancer
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
UA110370C2 (en) Conjugates of amatoxin with improved linkages
PT2155188E (pt) Métodos e composições para o tratamento de cancro recorrente
WO2008081927A1 (fr) Procédé de traitement d'un cancer utilisant un agent anti-cancer en combinaison
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE469158T1 (de) Heteroalkylgebundene pyrimidinderivate
WO2008105852A3 (fr) Nanoparticules mucoadhésives pour traitement anticancéreux
MY184464A (en) Combined use of cholestanol derivative
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
WO2014089177A3 (fr) Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
EP2425874A3 (fr) Utilisation de la vitamine D et un agent thérapeutique supplémentaire pour le traitment du cancer
WO2010065329A3 (fr) Nanoparticules pour le traitement du cancer
WO2007053284A3 (fr) Methode de traitement d'un cancer du sein au moyen de 17-aag ou 17-ag ou d'un promedicament d'un de ceux-ci conjointement avec un inhibiteur her2
WO2007025303A3 (fr) Antiandrogenes non steroidiens
NZ610851A (en) Compounds and compositions for the treatment of cancer
WO2010087976A3 (fr) Conjugués anticancéreux protéine-platine
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
WO2007056236A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10755341

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10755341

Country of ref document: EP

Kind code of ref document: A2